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Comparison of free versus nanoparticle encapsulated drugs on 3T3 cell differentiation
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Nanoparticle Synthesis

Introduction

We have successfully synthesized
PLGA
nanoparticles
containing
AS1842856
and
DMPC/DPPC
liposomes containing BalfilomycinA1 or CL316243 using a turbulent jet
mixing
approach.
A
targeting
peptide, P3 which binds to prohibitin
in white adipose tissue vasculature,
was conjugated to the PLGA
nanoparticles. The particle size, as
measured
by
dynamic
light
scattering, was found to range
between 140-210 nm for the PLGA
nanoparticles and 90-220 nm for the
liposomes. Particles produced this
way have shown stability at 4℃ for 4
weeks.

The scope of this project was to design, synthesize and test targeted
nanoparticles containing hydrophobic and hydrophilic drugs that promote
browning in adipose tissue. For hydrophilic drugs the use of liposomes and their
hydrophilic core is more useful than the PLGA nanoparticles which have
hydrophobic cores. The inhibition of the FOXO1 pathway and modulation of
autophagy in adipose tissue can promote browning of white adipose tissue, or
an energy burning state where excess energy is burned as heat instead of
stored in the cell. If successful, these drugs would offer an alternative treatment
for obesity where changes to the patient's lifestyle, such as dieting and frequent
exercise, have had little desired effect. The targeted nature of this treatment
offers several potential benefits over free drug doses. The results will
demonstrate whether encapsulation and targeted encapsulation improves the
response and/or allows for a lower drug dose as compared to the free drug.

Theoretical

Figure 3. Process for synthesizing Nanoparticles (2)
The
FOXO1
pathway
interacts with the insulin
signal in cells and the
inhibition of this pathway in
many cell types throughout
the body may have various
unintended
side-effects.
Targeted drug delivery using
nanoparticles may result in a
more efficient transfer of the
drug to the adipose tissue
and may allow for a lower
active
drug-load
for
treatment.

Cell Differentiation

Figure 1. Proposed Drug-Interaction Mechanism

Nanoparticle Structure (Liposomes Only)
1.
2.

3.
4.

Drugs : Bafilomycin A1 or
CL 316,243
Lipid: Skeleton of the particle,
structural integrity is key since we
don’t want premature release of
the drug.
PEG: Provides protection from
surroundings in vivo
Marker (P3): Necessary for cell
identification. Specific to the cell
we are trying to target

Figure 2. Structure of Liposomal Nanoparticles (1)

Figure 4. Control 3T3 cells(Fibroblasts)

We are currently testing the free
drugs and nanoparticle encapsulated
drugs using the 3T3 cell line. FOXO1
and autophagy inhibitors can prevent
differentiation of 3T3 cells into
preadipocytes. The 3T3 cells have
been successfully differentiated into
preadipocytes as measured using Oil
Red O staining and dose response
testing is ongoing. The large blue
areas stained are the cell nuclei, this
helps with identification of individual
cells. The smaller red areas are the
areas of interest for our treatment
Differentiation Procedure
We differentiate the 3T3 fibroblasts by
exposing them to a rosiglitazone
solution followed by insulin exposure.
After exposure, there are 8 more days
of continued growth in basal media, to
replicate in vivo conditions, the cell
differentiation procedure’s effects are
visible. The total procedure last 10-12
days.

Figure 5. Differentiated 3T3 cells(Pre-adipocytes)

Experimental Design

Figure 6. Well-Plate Schematic for Drug and Nanoparticle Exposure

Expected Results
During the standard differentiation of 3T3 cells, the cells develop lipid dense areas
within each cell that can be visibly identified using Oil Red O staining. The exposure of
cells to FoxO1 inhibitors reduces the formation of these lipid dense regions. The
exposure of cells to nanoparticle encapsulated drugs should significantly reduce the
required drug-load or increase the efficacy of similar drug loads to free drug
concentrations; an amplification of the drugs effects should be observed when
encapsulated and targeted.

Current Work
We are currently working on exposing the cells to the drug in the manner displayed
under the Experimental Design section. We are designing the nanoparticles to carry a
drug concentration of 6 mg/ml which requires further experimentation, the current drug
concentration is at 2 mg/ml which has proven unresponsive in in vivo tests carried out
by our collaborator.

Acknowledgements/References
We want to thank our collaborator Dr. Cheng for his contributions to the understanding
of the effects of the FoxO1 inhibitors. Without the advice and continued support of Dr.
Lewinski this project would not have been possible, we want to greatly thank her for
everything she has done.
1 Rani, Dash Tapaswi. “Liposome as a potential drug delivery system: a review.” (2013).
2 Gharib, R.; Greige-Gerges, H.; Fourmentin, S.; Charcosset, C.; Auezova, L. Liposomes incorporating
cyclodextrin–drug inclusion complexes: Current state of knowledge.2015, Carbohydrate Polymers. 129.

